Genesis Molecular AI

Active#11 worldwide · AI drug discovery

AI drug discovery

HQUnited States

Last roundStrategic equity · May 2026

Uback rankings

Ranking	Tier	Rank	Edition	Next update
AI drug discovery · worldwide	Top 13	#11	Edition 0 (beta) · Sep 2026	21 Nov 2026

Rank historySep 2026 · #11 AI drug discoveryFirst edition: no movements yet.

Estimated valuation

AI · AI drug discovery ranking (worldwide)

≈ USD 600MUSD 300M–1.2bn · Hundreds of M$ Low confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Anchor: Last known equity round: Strategic equity · USD 40M · May 2026

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

Date	Round	Amount	Type	Investors	Source
May 2026	Strategic equity	USD 40M	Equity	Incyte	research.contrary.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Genesis Molecular AI as a PDF, on one of three angles only:

ValuationWhat is Genesis Molecular AI worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

Genesis Molecular AI is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in ai drug discovery Name Genesis Molecular AI as a preferred company (measures demand, promises nothing)

AI drug discovery poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Genesis Molecular AI?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements2 sources

Read by the AI at the next edition.

Comparable companies in ai drug discovery

Full ai drug discovery ranking →

Basecamp Research#10United KingdomHundreds of M$Cradle#12NetherlandsHundreds of M$Owkin#9FranceHundreds of M$Aqemia#13FranceHundreds of M$

Investors in Genesis Molecular AI: Incyte

Sources. research.contrary.com · investor.incyte.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.